Thus, to improve the poor outcomes of CRC patients with metastasis, it may be therapeutically useful to consider ways suppress THBS2 or BGN expression in CRC and combine this with 5‐FU treatment as a combination treatment strategy. Here, THBS2 is linked to colorectal carcinoma.